Anti-TNF-α therapies: the next generation (original) (raw)

• Carswell, E. A. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72, 3666–3670 (1975).
  CAS PubMed PubMed Central Google Scholar
• Wiemann, B. & Starnes, C. O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64, 529–564 (1994).
  Article CAS PubMed Google Scholar
• Kawakami, M. & Cerami, A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J. Exp. Med. 154, 631–639 (1981).
  CAS PubMed Google Scholar
• Beutler, B., Mahoney, J., Le Trang, N., Pekala, P. & Cerami, A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J. Exp. Med. 161, 984–995 (1985). References 1 and 4 are the original articles describing the anti-tumour activity of TNF and cachectin.
  CAS PubMed Google Scholar
• Beutler, B. et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316, 552–554 (1985).
  CAS PubMed Google Scholar
• Pennica, D., Hayflick, J. S., Bringman, T. S., Palladino, M. A. & Goeddel, D. V. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc. Natl Acad. Sci. USA 82, 6060–6064 (1985).
  CAS PubMed PubMed Central Google Scholar
• Pennica, D. et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312, 724–729 (1984). This manuscript describes the cloning of complementary DNA for human TNF-α.
  CAS PubMed Google Scholar
• Kriegler, M., Perez, C., DeFay, K., Albert, I. & Lu, S. D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53, 45–53 (1988).
  CAS PubMed Google Scholar
• Alexopoulou, L., Pasparakis, M. & Kollias, G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur. J. Immunol. 27, 2588–2592 (1997).
  CAS PubMed Google Scholar
• Kusters, S. et al. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur. J. Immunol. 27, 2870–2875 (1997).
  CAS PubMed Google Scholar
• Josephs, M. D. et al. Lipopolysaccharide and d-galactosamine-induced hepatic injury is mediated by TNF-α and not by Fas ligand. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278, R1196–R1201 (2000).
  CAS PubMed Google Scholar
• Moss, M. L. et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 385, 733–736 (1997).
  CAS PubMed Google Scholar
• Peschon, J. J. et al. An essential role for ectodomain shedding in mammalian development. Science 282, 1281–1284 (1998).
  CAS PubMed Google Scholar
• Evans, T. J. et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor–immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J. Exp. Med. 180, 2173–2179 (1994).
  CAS PubMed Google Scholar
• Grell, M., Wajant, H., Zimmermann, G. & Scheurich, P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl Acad. Sci. USA 95, 570–575 (1998).
  CAS PubMed PubMed Central Google Scholar
• Tartaglia, L. A., Pennica, D. & Goeddel, D. V. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J. Biol. Chem. 268, 18542–18548 (1993).
  CAS PubMed Google Scholar
• Grell, M., Becke, F. M., Wajant, H., Mannel, D. N. & Scheurich, P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur. J. Immunol. 28, 257–263 (1998).
  CAS PubMed Google Scholar
• Alexander-Miller, M. A., Derby, M. A., Sarin, A., Henkart, P. A. & Berzofsky, J. A. Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor α receptor II-mediated apoptosis of cytotoxic T lymphocytes. J. Exp. Med. 188, 1391–1399 (1998).
  CAS PubMed PubMed Central Google Scholar
• Zheng, L. et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348–351 (1995).
  CAS PubMed Google Scholar
• Van Zee, K. J. et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc. Natl Acad. Sci. USA 89, 4845–4849 (1992).
  CAS PubMed PubMed Central Google Scholar
• Seckinger, P., Isaaz, S. & Dayer, J. M. A human inhibitor of tumor necrosis factor α. J. Exp. Med. 167, 1511–1516 (1988).
  CAS PubMed Google Scholar
• Engelmann, H., Aderka, D., Rubinstein, M., Rotman, D. & Wallach, D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 264, 11974–11980 (1989).
  CAS PubMed Google Scholar
• Olsson, I. et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur. J. Haematol. 42, 270–275 (1989). Reference 20–23 are the original descriptions of the TNF-receptor-binding proteins.
  CAS PubMed Google Scholar
• Douni, E. et al. Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J. Inflamm. 47, 27–38 (1995).
  CAS PubMed Google Scholar
• Douni, E. & Kollias, G. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin α, or the p55TNF-R. J. Exp. Med. 188, 1343–1352 (1998).
  CAS PubMed PubMed Central Google Scholar
• Butler, D. M. et al. DBA/1 mice expressing the human TNF-α transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J. Immunol. 159, 2867–2876 (1997).
  CAS PubMed Google Scholar
• Mussener, A., Litton, M. J., Lindroos, E. & Klareskog, L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin. Exp. Immunol. 107, 485–493 (1997).
  CAS PubMed PubMed Central Google Scholar
• van den Berg, W. B. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin. Arthritis Rheum. 30, 7–16 (2001).
  CAS PubMed Google Scholar
• Haralambous, S., Plows, D., Kollias, G. Attenuation of transgenic TNF triggered arthritis in IL-1R deficient mice. Europ. Cytokine Netw. (abstract) 9, 408 (1998).
  Google Scholar
• Joosten, L. A. et al. IL-1α β-blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J. Immunol. 163, 5049–5055 (1999).
  CAS PubMed Google Scholar
• Probert, L., Plows, D., Kontogeorgos, G. & Kollias, G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur. J. Immunol. 25, 1794–1797 (1995).
  CAS PubMed Google Scholar
• Di Giovine, F. S., Nuki, G. & Duff, G. W. Tumour necrosis factor in synovial exudates. Ann. Rheum. Dis. 47, 768–772 (1988).
  CAS PubMed PubMed Central Google Scholar
• Buchan, G. et al. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin. Exp. Immunol. 73, 449–455 (1988).
  CAS PubMed PubMed Central Google Scholar
• Saxne, T., Palladino, M. A., Jr., Heinegard, D., Talal, N. & Wollheim, F. A. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31, 1041–1045 (1988). References 32–34 describe the presence of TNF-α in rheumatoid arthritis synovial fluid and serum.
  CAS PubMed Google Scholar
• Taylor, P. C. Anti-TNF-α therapy for rheumatoid arthritis: an update. Intern. Med. 42, 15–20 (2003).
  CAS PubMed Google Scholar
• Christen, U., Thuerkauf, R., Stevens, R. & Lesslauer, W. Immune response to a recombinant human TNFR55–IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Hum. Immunol. 60, 774–790 (1999).
  CAS PubMed Google Scholar
• Baecklund, E., Ekbom, A., Sparen, P., Feltelius, N. & Klareskog, L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317, 180–181 (1998).
  CAS PubMed PubMed Central Google Scholar
• Baecklund, E. et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum. 48, 1543–1550 (2003).
  PubMed Google Scholar
• Ekstrom, K. et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 48, 963–970 (2003). References 37–39 describe the potential risks associated with RA and anti-TNF therapies.
  PubMed Google Scholar
• Thalidomide approved. Posit. Aware 9, 16 (1998).
• Rajkumar, S. V. et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin. Proc. 75, 897–901 (2000).
  CAS PubMed Google Scholar
• Rajkumar, S. V. & Witzig, T. E. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat. Rev. 26, 351–362 (2000).
  CAS PubMed Google Scholar
• Rajkumar, S. V. Thalidomide in multiple myeloma. Oncology (Huntingt.) 14, 11–16 (2000).
  CAS Google Scholar
• Rajkumar, S. V. et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 15, 1274–1276 (2001).
  CAS PubMed Google Scholar
• Rajkumar, S. V. Current status of thalidomide in the treatment of cancer. Oncology (Huntingt.) 15, 867–874; discussion 877–879 (2001).
  CAS Google Scholar
• Nau, H. Species differences in pharmacokinetics and drug teratogenesis. Environ. Health Perspect. 70, 113–129 (1986).
  CAS PubMed PubMed Central Google Scholar
• Neubert, R., Hinz, N., Thiel, R. & Neubert, D. Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci. 58, 295–316 (1996).
  CAS PubMed Google Scholar
• Neubert, D., Heger, W., Merker, H. J., Sames, K. & Meister, R. Embryotoxic effects of thalidomide derivatives in the non-human primate Callithrix jacchus. II. Elucidation of the susceptible period and of the variability of embryonic stages. Arch. Toxicol. 61, 180–191 (1988).
  CAS PubMed Google Scholar
• Klug, S. et al. Embryotoxic effects of thalidomide derivatives in the non-human primate Callithrix jacchus. 5. Lack of teratogenic effects of phthalimidophthalmide. Arch. Toxicol. 68, 203–205 (1994).
  CAS PubMed Google Scholar
• Dredge, K. et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168, 4914–4919 (2002).
  CAS PubMed Google Scholar
• Dredge, K. et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer 87, 1166–1172 (2002).
  CAS PubMed PubMed Central Google Scholar
• Marriott, J. B. et al. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Res. 63, 593–599 (2003).
  CAS PubMed Google Scholar
• Dredge, K., Marriott, J. B. & Dalgleish, A. G. Immunological effects of thalidomide and its chemical and functional analogs. Crit. Rev. Immunol. 22, 425–437 (2002).
  CAS PubMed Google Scholar
• Dredge, K., Dalgleish, A. G. & Marriott, J. B. Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs 14, 331–335 (2003).
  CAS PubMed Google Scholar
• Burnouf, C. & Pruniaux, M. P. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr. Pharm. Des. 8, 1255–1296 (2002).
  CAS PubMed Google Scholar
• Barnette, M. S. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog. Drug. Res. 53, 193–229 (1999).
  CAS PubMed Google Scholar
• Giembycz, M. A. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi. Arch. Chest Dis. 57, 48–64 (2002).
  CAS PubMed Google Scholar
• Spina, D. Theophylline and PDE4 inhibitors in asthma. Curr. Opin. Pulm. Med. 9, 57–64 (2003).
  CAS PubMed Google Scholar
• Han, J., Lee, J. D., Tobias, P. S. & Ulevitch, R. J. Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J. Biol. Chem. 268, 25009–25014 (1993).
  CAS PubMed Google Scholar
• Haddad, J. J. VX-745. Vertex Pharmaceuticals. Curr. Opin. Investig. Drugs 2, 1070–1076 (2001).
  CAS PubMed Google Scholar
• Rasmussen, H. S. & McCann, P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther. 75, 69–75 (1997).
  CAS PubMed Google Scholar
• Tsuji, F. et al. Differential effects between marimastat, a TNF-α converting enzyme inhibitor, and anti-TNF-α antibody on murine models for sepsis and arthritis. Cytokine 17, 294–300 (2002).
  CAS PubMed Google Scholar
• Roff, M. et al. Role of IκBα ubiquitination in signal-induced activation of NFκB in vivo. J. Biol. Chem. 271, 7844–7850 (1996).
  CAS PubMed Google Scholar
• Sen, R. & Baltimore, D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46, 705–716 (1986).
  CAS PubMed Google Scholar
• Birbach, A. et al. Signaling molecules of the NF-κB pathway shuttle constitutively between cytoplasm and nucleus. J. Biol. Chem. 277, 10842–10851 (2002).
  CAS PubMed Google Scholar
• O'Connell, M. A., Bennett, B. L., Mercurio, F., Manning, A. M. & Mackman, N. Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. J. Biol. Chem. 273, 30410–30414 (1998).
  CAS PubMed Google Scholar
• Lin, H., Chen, C. & Chen, B. D. Resistance of bone marrow-derived macrophages to apoptosis is associated with the expression of X-linked inhibitor of apoptosis protein in primary cultures of bone marrow cells. Biochem. J. 353, 299–306 (2001).
  CAS PubMed PubMed Central Google Scholar
• Adams, J. Preclinical development of velcade (bortezomib; formerly PS-341) for multiple myeloma. Eur. J. Haematol. 70, 265 (2003).
  Google Scholar
• Twombly, R. First proteasome inhibitor approved for multiple myeloma. J. Natl Cancer Inst. 95, 845 (2003).
  PubMed Google Scholar
• Lee, J. H., Koo, T. H., Hwang, B. Y. & Lee, J. J. Kaurane diterpene, kamebakaurin, inhibits NF-κB by directly targeting the DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-κB target genes. J. Biol. Chem. 277, 18411–18420 (2002).
  CAS PubMed Google Scholar
• Hwang, B. Y. et al. Kaurane diterpenes from I_sodon japonicus_ inhibit nitric oxide and prostaglandin E2 production and NF-κB activation in LPS-stimulated macrophage RAW264.7 cells. Planta Med. 67, 406–410 (2001).
  CAS PubMed Google Scholar
• Posadas, I. et al. Inhibition of the NF-κB signaling pathway mediates the anti-inflammatory effects of petrosaspongiolide M. Biochem. Pharmacol. 65, 887–895 (2003).
  CAS PubMed Google Scholar
• Hehner, S. P. et al. Sesquiterpene lactones specifically inhibit activation of NF-κB by preventing the degradation of IκB-α and IκB-β. J. Biol. Chem. 273, 1288–1297 (1998).
  CAS PubMed Google Scholar
• Sheehan, M. et al. Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol. Pharmacol. 61, 953–963 (2002).
  CAS PubMed Google Scholar
• Kwok, B. H., Koh, B., Ndubuisi, M. I., Elofsson, M. & Crews, C. M. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase. Chem. Biol. 8, 759–766 (2001).
  CAS PubMed Google Scholar
• Kim, E. J. et al. Suppression by a sesquiterpene lactone from Carpesium divaricatum of inducible nitric oxide synthase by inhibiting nuclear factor-κB activation. Biochem. Pharmacol. 61, 903–910 (2001). References 70–76 are representative articles describing natural product anti-inflammatory molecules.
  CAS PubMed Google Scholar
• Singh, S., Natarajan, K. & Aggarwal, B. B. Capsaicin (8-methyl-_N_-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-κB activation by diverse agents. J. Immunol. 157, 4412–4420 (1996).
  CAS PubMed Google Scholar
• Lange, R. W., Hayden, P. J., Chignell, C. F. & Luster, M. I. Anthralin stimulates keratinocyte-derived proinflammatory cytokines via generation of reactive oxygen species. Inflamm. Res. 47, 174–181 (1998).
  CAS PubMed Google Scholar
• Simeonova, P. P. & Luster, M. I. Iron and reactive oxygen species in the asbestos-induced tumor necrosis factor-α response from alveolar macrophages. Am. J. Respir. Cell. Mol. Biol. 12, 676–683 (1995).
  CAS PubMed Google Scholar
• Burke, J. R. et al. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J. Biol. Chem. 278, 1450–1456 (2003).
  CAS PubMed Google Scholar
• Manna, S. K., Bueso-Ramos, C., Alvarado, F. & Aggarwal, B. B. Calagualine inhibits nuclear transcription factors-κB activated by various inflammatory and tumor promoting agents. Cancer Lett. 190, 171–182 (2003).
  CAS PubMed Google Scholar
• Han, J., Thompson, P. & Beutler, B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 172, 391–394 (1990).
  CAS PubMed Google Scholar
• Tracey, K. J. The inflammatory reflex. Nature 420, 853–859 (2002).
  CAS PubMed Google Scholar
• Dixon, T. C., Meselson, M., Guillemin, J. & Hanna, P. C. Anthrax. N. Engl. J. Med. 341, 815–826 (1999).
  CAS PubMed Google Scholar
• Guidi-Rontani, C. The alveolar macrophage: the Trojan horse of Bacillus anthracis. Trends Microbiol. 10, 405–409 (2002).
  CAS PubMed Google Scholar
• Hanna, P. Lethal toxin actions and their consequences. J. Appl. Microbiol. 87, 285–287 (1999).
  CAS PubMed Google Scholar
• Hanna, P. C., Acosta, D. & Collier, R. J. On the role of macrophages in anthrax. Proc. Natl Acad. Sci. USA 90, 10198–10201 (1993).
  CAS PubMed PubMed Central Google Scholar
• Mock, M. & Fouet, A. Anthrax. Annu. Rev. Microbiol. 55, 647–671 (2001).
  CAS PubMed Google Scholar
• Bradley, K. A., Mogridge, J., Mourez, M., Collier, R. J. & Young, J. A. Identification of the cellular receptor for anthrax toxin. Nature 414, 225–229 (2001).
  CAS PubMed Google Scholar
• Petosa, C., Collier, R. J., Klimpel, K. R., Leppla, S. H. & Liddington, R. C. Crystal structure of the anthrax toxin protective antigen. Nature 385, 833–838 (1997).
  CAS PubMed Google Scholar
• Leppla, S. H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl Acad. Sci. USA 79, 3162–3166 (1982).
  CAS PubMed PubMed Central Google Scholar
• Duesbery, N. S. et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280, 734–737 (1998).
  CAS PubMed Google Scholar
• Park, J. M., Greten, F. R., Li, Z. W. & Karin, M. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 297, 2048–2051 (2002).
  CAS PubMed Google Scholar
• Vitale, G., Bernardi, L., Napolitani, G., Mock, M. & Montecucco, C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 352, 739–745 (2000).
  CAS PubMed PubMed Central Google Scholar
• Vitale, G. et al. Anthrax lethal factor cleaves the N-terminus of MAPKKS and induces tyrosine/threonine phosphorylation of MAPKS in cultured macrophages. J. Appl. Microbiol. 87, 288 (1999).
  CAS PubMed Google Scholar
• Pellizzari, R., Guidi-Rontani, C., Vitale, G., Mock, M. & Montecucco, C. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNγ-induced release of NO and TNF-α. FEBS Lett. 462, 199–204 (1999).
  CAS PubMed Google Scholar
• Tang, G. & Leppla, S. H. Proteasome activity is required for anthrax lethal toxin to kill macrophages. Infect. Immun. 67, 3055–3060 (1999).
  CAS PubMed PubMed Central Google Scholar
• Amir, R., Ciechanover, A. & Cohen, S. The ubiquitin-proteasome system: the relationship between protein degradation and human diseases. Harefuah 140, 1172–1176, 1229 (2001).
  CAS PubMed Google Scholar
• Friedlander, A. M. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261, 7123–7126 (1986).
  CAS PubMed Google Scholar
• Roberts, J. E., Watters, J. W., Ballard, J. D. & Dietrich, W. F. Ltx1, a mouse locus that influences the susceptibility of macrophages to cytolysis caused by intoxication with Bacillus anthracis lethal factor, maps to chromosome 11. Mol. Microbiol. 29, 581–591 (1998).
  CAS PubMed Google Scholar
• Welkos, S. L. & Friedlander, A. M. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb. Pathog. 4, 53–69 (1988).
  CAS PubMed Google Scholar
• Welkos, S. L., Keener, T. J. & Gibbs, P. H. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect. Immun. 51, 795–800 (1986).
  CAS PubMed PubMed Central Google Scholar
• Welkos, S. L. & Friedlander, A. M. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5, 127–139 (1988).
  CAS PubMed Google Scholar
• Watters, J. W., Dewar, K., Lehoczky, J., Boyartchuk, V. & Dietrich, W. F. Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor. Curr. Biol. 11, 1503–1511 (2001).
  CAS PubMed Google Scholar
• Kim, S. O. et al. Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-α. J. Biol. Chem. 278, 7413–7421 (2003). References 91, 97 and 105 describe the potential roles of TNF-α and proteasome inhibition and in anthrax.
  CAS PubMed Google Scholar